• Press Releases.png

    Press Releases

OmniComm® Systems Announces Major Milestone Achievement of over 4,000 Clinical Trials

March 25, 2014

CONTACT :

Dennis Constantinou
OmniComm Systems, Inc.
+1.877.468.6332
dconstantinou@omnicomm.com

Download Press Release

OmniComm Systems solutions expand utilization of EDC globally

Fort Lauderdale, FL, March 25, 2014 – OmniComm Systems, Inc. (OTC: OMCM), a global leading provider of clinical data management solutions for clinical trials, today announced its electronic data capture (EDC) solutions have been used in more than 4,000 live or completed clinical trials in over 55 countries across more than 30 therapeutic areas. The company’s EDC solutions are widely accepted and utilized by pharmaceutical; biotechnology; contract research organizations; academic research centers and medical device companies of all sizes in all clinical trial phases. OmniComm’s EDC technologies are embraced by the industry by significantly streamlining clinical processes through innovation, automation and interoperability.

The announcement comes as the company released its latest version of TrialMaster® its flagship EDC product. This new release includes over 300 new innovative productivity and functionality enhancements, including TrialMaster unique features like auto-redaction for faster and more efficient centralized and risked based monitoring, as well as major new automation features for exporting data utilizing OmniComm’s award winning Export Utility.

TrialMaster is a key part of OmniComm’s technology portfolio that includes TrialOne®, eClinical Suite™ and Promasys®. TrialOne offers end-to-end solutions for unparalleled Phase I study automation; eClinical Suite provides a comprehensive, functionally-rich solution to streamline clinical trial processes; Promasys was developed to meet the unique EDC demands of Investigator Initiated Studies and academic researcher projects. With over 15 major product releases within the last five years OmniComm continues to lead the industry in progressive and innovative EDC technology.

“This significant milestone is proof of the industry’s broad acceptance of OmniComm’s best-of-breed approach to developing EDC solutions,” said Stephen Johnson, president, OmniComm Systems. “Our approach has been to develop targeted solutions for specific needs - TrialOne for Phase I Clinic Automation, TrialMaster for traditional phase I-IV clinical trials, eClinical Suite for hybrid trials, and Promasys for investigator initiated trials. We are thankful for our 200+ customers and will continue to develop innovative solutions that meet their particular needs.”

About OmniComm Systems

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.

Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Trademarks

OmniComm and TrialMaster are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.